S

Stryker

Manufactures orthopedic and surgical medical devices

Product Manager - Hip & Field Marketing

Full-Time
No salary listed
Mid
Bachelor's
Tokyo, Japan
HybridHybrid or onsite work in Tokyo.
Growth & MarketingProduct Marketing

About the job

Requirements
  • A bachelor's degree or equivalent qualification.
  • Excellent verbal and written communication skills in Japanese.
  • Willingness and commitment to continuously learn and develop English proficiency, product knowledge, understanding of healthcare systems, and market trends.
  • A demonstrated track record of driving sales growth and market penetration.
  • For external candidates, business-level English proficiency is required.
  • For external candidates, at least 3 years of experience in product management or marketing roles within the medical device industry.
Responsibilities
  • Prepare marketing plans for specified aspects or components of Stryker products, focusing on appropriate target audiences.
  • Obtain market intelligence on local product development and competitor activities.
  • Ensure field staff receive appropriate training to effectively deliver key selling messages.
  • Establish relationships with the US and APAC Marketing Departments, prepare reports as requested, and appropriately forward territory information regarding Stryker products.
  • Organize and perform workshops, presentations, and demonstrations.
  • Contribute to identifying key opinion leaders and lead communication with them.
  • Support the sales force by attending demonstrations and key opinion leader visits.
  • Support the sales team in improving technical knowledge about the product.
  • Manage budgets for all initiated marketing activities.
  • Continuously develop relevant skills and knowledge.
  • Work closely with Logistics for quarterly safety stock reviews.
  • Support development and implementation of the company quality system.
  • Lead the team efficiently to optimize outcomes consistent with the code of conduct.
  • Work closely with Regulatory Affairs and Quality Assurance officers on registration documentation.

About the company

Stryker makes medical devices for hospitals, surgical centers and emergency responders, spanning joint implants, surgical instruments and patient transport equipment. Its Mako platform assists surgeons with joint replacement, while its neurotechnology products support brain and spine procedures and stroke treatment. Clinicians use its equipment during surgery and emergency care, and the company earns money by selling implants, disposable products and capital equipment through direct sales teams and distributors. The business also supplies training and technical support for healthcare providers using its devices. Stryker was founded in 1941 and is headquartered in Portage, Michigan.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand supports growth: July 2026 Stryker results show organic sales rose 9%, with reported sales reaching $6.6 billion.
  • Service extends equipment sales: Stryker's ProCare contracts bundle preventive maintenance, repairs and original manufacturer parts.
  • Relocation is available for Worcester technicians: Stryker's live transport service opening also lists 12 paid holidays.

What critics are saying

  • Operational failures reach customers: March 2026 cyberattack disrupted Stryker's ordering, manufacturing and shipping.
  • Older implants retain legal exposure: Stryker's recall estimates include Rejuvenate, LFIT V40 and legacy Wright hip products.
  • Field service demands travel: Stryker's northern Minnesota opening lists 80% travel plus evening or weekend call.

What makes Stryker unique

  • Mako combines imaging and physical guidance: Stryker uses CT-based planning and haptic boundaries during hip replacement.
  • Discarded devices return to service: Stryker's Sustainability Solutions reprocesses medical equipment for hospitals across the U.S. and Canada.
  • Transport extends its technology outside hospitals: Stryker's Power-LOAD supports stretchers while loading and unloading ambulances.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical & prescription plans
  • Supplemental health benefits
  • Flexible Spending accounts
  • Employee Assistance Program
  • Short-term & long-term disability
  • Tuition reimbursement
  • 401(k) plan
  • Employee Stock Purchase Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 29th, 2026
Stryker misses Q3 forecasts with $753M profit on $6.52B revenue

Stryker reported third-quarter profit of $753 million, or $1.96 per share, on Thursday. The Michigan-based medical device maker's adjusted earnings, which exclude asset impairment and amortisation costs, were $3.52 per share. Both results missed Wall Street forecasts. Analysts surveyed by Zacks Investment Research expected earnings of $3.56 per share and revenue of $6.58 billion; Stryker posted revenue of $6.52 billion. The company expects full-year earnings of $14.80 to $14.90 per share.

Associated Press
Oct 29th, 2026
Stryker Q3 sales rise 7.7% to $6.5B, but miss expectations; $3B added to buyback

Stryker reported third-quarter net sales of $6.5 billion, up 7.7% from a year earlier. Organic sales also rose 7.7%, driven mainly by higher unit volume. Reported net earnings fell 12.3% to $753 million, or $1.96 per diluted share, down 11.7%. Adjusted earnings per share rose 10.3% to $3.52, and adjusted operating margin rose 60 basis points to 26.2%. MedSurg and Neurotechnology sales grew 9.2% to $3.7 billion. Orthopaedics sales rose 5.7% to $2.9 billion. Chief executive officer Kevin A. Lobo said the results fell short of expectations, but he expects a solid fourth quarter. Stryker now expects 2026 organic sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90. It bought back $1.0 billion of stock in the quarter, and its board added $3.0 billion to the repurchase programme.

Yahoo Finance
Oct 28th, 2026
Stryker lags peers with 8.5% growth as plant problems, not hospitals, hit sales

Stryker's stock has lost 20.2% over the past 12 months, dividends included, while the S&P 500 returned 15.0%. Its revenue grew 8.5% over the latest four quarters, slower than four of its five peers, including Boston Scientific (13.5%) and Intuitive Surgical (20.5%). Management says hospital demand is steady. It blames the slowdown on a cybersecurity incident that halted manufacturing and on supply problems in peripheral vascular products. First-quarter fiscal 2026 revenue grew just 2.6%, and operating margin fell to 15.5%. Margin recovered to 25.2% in the second quarter. The stock fell 8.8% on September 8, 2026, after the chief financial officer said the vascular issue was unresolved. Third-quarter results are due October 29, 2026. Spencer Stiles will succeed Kevin Lobo as chief executive officer on January 1, 2027.

Stryker Corporation
Oct 27th, 2026
Stryker Completes Acquisition of MAKO Surgical Corp.

Kalamazoo, Michigan - December 17, 2013 - Stryker Corporation (NYSE:SYK) announced today the completion of its previously announced acquisition of MAKO Surgical Corp., a pioneer in the advancement of robotic arm assisted surgery in orthopaedics. "We're excited to welcome MAKO into our organization and combine their expertise in robotic arm assisted surgery with Stryker's innovations in joint reconstruction to further advance the growth of this compelling technology. The long-term potential offered by this technology platform holds the promise of transforming reconstructive surgery, increasing patient satisfaction and enhancing the experience for surgeons and hospitals," said Kevin A. Lobo, President and Chief Executive Officer. As indicated in the September 25, 2013 press release, the transaction is expected to be dilutive to Stryker's adjusted earnings per share excluding acquisition and integration-related charges by approximately $0.10 - $0.12 in the first full year, neutral in

Yahoo Finance
Oct 21st, 2026
P&G and Stryker: two dividend stocks to hold for decades

Procter & Gamble and Stryker are two dividend stocks suited to long-term holders, according to the article. Both sell products people need in any economy. P&G has raised its dividend for 70 consecutive years. In fiscal 2026, it posted net sales of about $87 billion, up 3%, and net earnings of $16.1 billion. It returned more than $15 billion to shareholders, including $10.2 billion in dividends. Organic sales and core earnings per share each grew just 1%. Stryker has raised its dividend for more than three decades. Second-quarter 2026 revenue rose 9.4% to $6.6 billion, and adjusted earnings per share climbed 17.9% to $3.69. Demand should gain from an ageing US population, though recalls, acquisition costs, and hospital spending pressures remain risks.